Paclitaxel combined with chemotherapy in the treatment of advanced breast cancer
- VernacularTitle:含紫杉醇的联合化疗方案治疗晚期乳腺癌
- Author:
Fengshou JIANG
;
Yubei SUN
;
Bing HU
- Publication Type:Journal Article
- Keywords:
breast neoplasms;
paclitaxel;
combined chemotherapy
- From:China Oncology
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose: To evaluate the therapeutic effect and toxicities of paclitaxel combined chemotherapy regimens in the treatment of advanced breast cancer. Methods: 30 cases with advanced breast cancer verified by pathology were given routinely standard anti-hypersensitive treatment before systematic chemotherapy. In combination regimens, Taxol was given 175 mg/m by intravenous( i. v.) infusion on dayl, cyclophosphamide 400mg/m i. v. on day 1, day 8, 5-fluouracil 500 mg/ m i. v. on day 1, day 8. Drugs were repeated every 28 days and one course consisted of 2 cycles. Results: 3 patients showed complete response and 16 patients showed partial response. The overall response rate was 63. 3%. The median duration of remission was 9 months. The major toxic effects including myelosuppression, myalgia/arthralgta and peripheral neuropathy, were mild or moderate. There was no hypersensitivity. The side-effects disappeared after stopping chemotherapy. Conclusions: Taxol combined with chemotherapy regimens are an effective treatment for patients with advanced breast cancer, The toxicity of the treatment are tolerated by the patients. These regimens are worthy of recommendation as second-line chemotherapy.
